LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on ...

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert. Calquence (acalabrutinib) and ...

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...